Acorda Therapeutics

Acorda Therapeutics is an American biotechnology company based in Ardsley, New York. The company primarily focuses on the development of therapies that improve neurological function in people with multiple sclerosis, spinal cord injury, and other disorders of the nervous system.

History

Acorda Therapeutics was founded in 1995 by Dr. Ron Cohen, a neurologist and former National Institutes of Health (NIH) researcher. The company was initially established to develop treatments for spinal cord injury and related neurological conditions.

Products

Acorda Therapeutics has developed several products for the treatment of neurological disorders. The company's first approved drug, Zanaflex (tizanidine), is a short-acting drug for the management of spasticity. The company also developed Ampyra (dalfampridine), an oral medication designed to improve walking in patients with multiple sclerosis.

Research and Development

Acorda Therapeutics has a robust research and development program. The company is currently developing several new therapies for neurological disorders, including treatments for Parkinson's disease, stroke, and epilepsy.

Financial Performance

Acorda Therapeutics is a publicly traded company listed on the NASDAQ stock exchange. The company's financial performance is closely watched by investors and analysts in the biotechnology sector.

Controversies

Like many biotechnology companies, Acorda Therapeutics has faced controversies. These have included patent disputes and criticism over the pricing of its products.

See Also

• Biotechnology
• Neurology
• Pharmaceutical industry in the United States